The Super Jake Foundation awarded Principal Investigator, Paul Sondel, MD, PhD, professor, and Co-PI Amy Erbe-Gurel, PhD, assistant professor, both in the Division of Hematology, Oncology, Transplant, and Cellular Therapy, a two-year, $100,000 grant for their study, “Anti-GD2 x anti-CD40: A Potential New Treatment for Neuroblastoma.” This project will design and optimize a new drug in the laboratory to make sure it can bind to neuroblastoma and to immune cells, test whether anti-GD2 x anti-CD40 can activate immune cells to attach high-risk neuroblastoma without causing harmful reaction, and evaluate how well anti-GD2 x anti-CD40 works when combined with chemotherapy. The grant began February of this year and will run through February 2028.